, Tracking Stock Market Picks
Enter Symbol:

up 1,218.30 %

QUESTOR PHARMACEUTCL (QCOR) rated Outperform with price target $99 by Oppenheimer

Posted on: Wednesday,  Feb 26, 2014  9:25 AM ET by Oppenheimer

Oppenheimer rated Outperform QUESTOR PHARMACEUTCL (NASDAQ: QCOR) on 02/26/2014. Previously Oppenheimer rated Outperform QUESTOR PHARMACEUTCL (NASDAQ: QCOR) on 12/18/2008., when
the stock price was $7.10. Since then, QUESTOR PHARMACEUTCL has gained 1218.31% as of 08/14/2014's recent price of $93.60.
If you would have followed the previous Oppenheimer's recommendation on QCOR, you would have gained 1218.3% of your investment in 2065 days.

Questcor Pharmaceuticals, Inc. (Questcor) markets H.P. Acthar Gel (repository corticotropin injection), an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis (MS), and the treatment of nephrotic syndrome. H.P. Acthar Gel (Acthar) is not indicated for, but is also used in treating patients with infantile spasms (IS). The Company also markets Doral (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. As of December 31, 2008, Acthar was approved in the United States for the treatment of exacerbations associated with MS, nephrotic syndrome and many other conditions with an inflammatory component.

OppenheimerFunds, Inc. has been helping investors achieve their financial goals since 1960. We are one of the nation's largest and most respected asset management companies. At OppenheimerFunds, we believe that in order for you to reach your financial goals, your investments must perform. That is why investment excellence—over the long term and across the range of our products—is our highest priority. OppenheimerFunds and its controlled affiliates offer a broad range of products and services to individuals, corporations and institutions, including mutual funds, separately managed accounts, investment management for institutions, hedge fund products, qualified retirement plans and subadvisory investment-management services.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/26/2014 9:25 AM Buy
74.21 99.00
as of 10/17/2014
1 Week   
1 Month   
3 Months down  -0.98 %
1 YTD up  71.90 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/19/2013 8:25 AM Buy
65.51 73.00
7/31/2013 8:25 AM Buy
60.09 73.00
6/21/2013 8:25 AM Buy
44.89 57.00
9/20/2012 8:25 AM Buy
28.13 65.00
9/18/2012 8:25 AM Buy
51.60 69.00
12/8/2011 8:25 AM Buy
42.68 53.00
10/26/2011 8:25 AM Buy
39.21 45.00
7/27/2011 8:25 AM Buy
30.06 35.00
5/13/2011 9:25 AM Buy
23.09 27.00
4/11/2011 8:25 AM Buy
18.93 23.00
12/14/2010 8:25 AM Buy
15.30 19.00
12/18/2008 8:25 AM Buy
7.10 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy